Alpha 2.0
Login Register
» Authors » Peter Gergely

Peter Gergely

Explore the profile of Peter Gergely including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 40
Citations 503
Followers 0
Related Specialties
General Medicine
History of Medicine
Rheumatology
Top 10 Co-Authors
Gyula Poor
James S Rush
Eszter Nagy
Laszlo Potor
Alexandre Avrameas
Jozsef Balla
Gyorgy Balla
Pascal Espie
Zoltan Hendrik
Gabor Mehes
Published In
Orv Hetil
Ann Rheum Dis
Int J Mol Sci
Pathol Oncol Res
J Rheumatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Defining immune reset: achieving sustained remission in autoimmune diseases
Junt T, Calzascia T, Traggiai E, da Costa A, Gergely P, Schett G, et al.
Nat Rev Immunol . 2025 Mar; PMID: 40044810
Personalized cell therapies for autoimmune diseases - such as autologous haematopoietic stem cell transplantation and chimeric antigen receptor-expressing T cells - have the potential to achieve sustained remission in patients...
2.
Head or skull injury? Consequences of using mistranslated ICD diagnosis category: Multicenter, blinded, randomized controlled analysis
Fogarasi K, Simon G, Gatos A, Gyenes G, Gergely P, Patonai Z
J Forensic Leg Med . 2025 Jan; 110:102815. PMID: 39884214
Emergency care units in Hungary treat approximately 140-180 thousand head injuries of varying se'verity each year. These head injuries are mainly caused by traffic accidents, assaults, or domestic accidents. The...
3.
Identification of Protein Networks and Biological Pathways Driving the Progression of Atherosclerosis in Human Carotid Arteries Through Mass Spectrometry-Based Proteomics
Kallo G, Zaman K, Potor L, Hendrik Z, Mehes G, Toth C, et al.
Int J Mol Sci . 2025 Jan; 25(24. PMID: 39769427
Vulnerable atherosclerotic plaques, especially hemorrhaged lesions, are the major cause of mortalities related to vascular pathologies. The early identification of vulnerable plaques helps to stratify patients at risk of developing...
4.
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study
Fisher B, Szanto A, Ng W, Bombardieri M, Posch M, Papas A, et al.
Lancet Rheumatol . 2024 Jan; 2(3):e142-e152. PMID: 38263652
Background: Primary Sjögren's syndrome is an autoimmune disease that presents as dryness of the mouth and eyes due to impairment of the exocrine glands. To our knowledge, no systemic therapies...
5.
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study
GomezMancilla B, Meriggioli M, Genge A, Roubenoff R, Espie P, Dupuy C, et al.
J Clin Neurosci . 2023 Nov; 119:76-84. PMID: 37988976
Background: Increased morbidity in many patients with myasthenia gravis (MG) on long-term immunosuppression highlights the need for improved treatments. The aim of this study is to investigate the safety and...
6.
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial
Dorner T, Kaul M, Szanto A, Tseng J, Papas A, Pylvaenaeinen I, et al.
Ann Rheum Dis . 2023 Nov; 83(3):360-371. PMID: 37932009
Objectives: To evaluate the safety and efficacy of remibrutinib in patients with moderate-to-severe Sjögren's syndrome (SjS) in a phase 2 randomised, double-blind trial (NCT04035668; LOUiSSE (LOU064 in Sjögren's Syndrome) study)....
7.
First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MHV370, a Dual Inhibitor of Toll-Like Receptors 7 and 8, in Healthy Adults
Shisha T, Posch M, Lehmann J, Feifel R, Junt T, Hawtin S, et al.
Eur J Drug Metab Pharmacokinet . 2023 Aug; 48(5):553-566. PMID: 37532923
Background And Objective: MHV370, a dual antagonist of human Toll-like receptors (TLR) 7 and 8, suppresses cytokines and interferon-stimulated genes in vitro and in vivo, and  has demonstrated efficacy in...
8.
Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy
Hawtin S, Andre C, Collignon-Zipfel G, Appenzeller S, Bannert B, Baumgartner L, et al.
Cell Rep Med . 2023 May; 4(5):101036. PMID: 37196635
Genetic and in vivo evidence suggests that aberrant recognition of RNA-containing autoantigens by Toll-like receptors (TLRs) 7 and 8 drives autoimmune diseases. Here we report on the preclinical characterization of...
9.
Hydrogen sulfide as an anti-calcification stratagem in human aortic valve: Altered biogenesis and mitochondrial metabolism of HS lead to HS deficiency in calcific aortic valve disease
Combi Z, Potor L, Nagy P, Sikura K, Ditroi T, Juranyi E, et al.
Redox Biol . 2023 Feb; 60:102629. PMID: 36780769
Hydrogen sulfide (HS) was previously revealed to inhibit osteoblastic differentiation of valvular interstitial cells (VICs), a pathological feature in calcific aortic valve disease (CAVD). This study aimed to explore the...
10.
Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy
Dertschnig S, Gergely P, Finke J, Schanz U, Holler E, Holtick U, et al.
Transplant Cell Ther . 2022 Nov; 29(1):41.e1-41.e9. PMID: 36343893
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the sole curative option for patients with acute myelogenous leukemia. Outcomes are limited by leukemia relapse, graft-versus-host disease (GVHD), and abnormal immune reconstitution....